VIA
LXEO icon

Virtus Investment Advisers’s Lexeo Therapeutics LXEO Stock Holding History

Virtus Investment Advisers’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349K Buy
74,874
+46,964
+168% +$254K 0.08% 348
2026
Q1 		$160K Buy
27,910
+680
+2% +$4.82K 0.04% 439
2025
Q4 		$270K Buy
+27,230
New +$248K 0.07% 290

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Virtus Investment Advisers's LXEO Position: Q2 2026 in Review

Virtus Investment Advisers increased its Lexeo Therapeutics (LXEO) stake by 168% in Q2 2026, buying an estimated $254K and bringing the position to 74,874 shares worth $349K. The position accounts for 0.08% of the portfolio, ranked #348.

Virtus Investment Advisers first reported a position in LXEO in Q4 2025 and has held it in 3 quarters since. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Virtus Investment Advisers held 74,874 shares of Lexeo Therapeutics worth $349K as of Q2 2026.
  • Virtus Investment Advisers bought 46,964 Lexeo Therapeutics shares in Q2 2026, an estimated $254K.
  • Lexeo Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q2 2026, its #348 holding.
  • Virtus Investment Advisers first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.